Peptic Ulcer Disease Associated with Central Obesity

Song-Seng Loke 1,* and Wen-Cheng Li 2

1 Division of Geriatric Medicine, Department of Family Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123, Dapi Road, Niaosong District, Kaohsiung 80708, Taiwan
2 Department of Family Medicine, Chang Gung Memorial Hospital, Linkou Branch, College of Medicine, Chang-Gung University, Taoyuan 32023, Taiwan
* Correspondence: loke@cgmh.org.tw

Abstract: This retrospective cross-sectional study aimed to evaluate associations between peptic ulcer disease (PUD), bone mineral density, and metabolic syndrome (MetS) and its components in healthy populations. Data were collected from the health examination database of a tertiary medical center in southern Taiwan from January 2015 to December 2016. Subjects who had undergone metabolic factors assessment, upper gastrointestinal endoscopy, and dual energy X-ray absorptiometry scans were enrolled. In total, 5102 subjects were included, with mean age 52.4 ± 12.0 years. Among them, 1332 (26.1%) had PUD. Multivariate logistic regression analysis showed that age (OR 1.03, p < 0.001), male (OR 1.89, p < 0.001), diabetes (OR 1.23, p = 0.004), BMI (OR 1.03, p = 0.001), and GOT (OR 1, p = 0.003) are risk factors for PUD. Regarding MetS parameters, larger waist circumference (OR 1.26, p = 0.001) is associated with PUD, and high triglycerides (OR 1.20, 95% CI 1.01–1.43) is associated with gastric ulcer, while low HDL (OR 1.31, 95% CI 1.07–1.59) and osteoporosis (OR 1.44, 95% CI 1.08–1.91) are associated with duodenal ulcer. In conclusion, central obesity is associated with PUD in a middle-aged healthy population. Subjects with high triglycerides are prone to gastric ulcers, and those with osteoporosis and low HDL are prone to duodenal ulcers.

Keywords: peptic ulcer disease; metabolic syndrome; central obesity; health examination

1. Introduction

Peptic ulcer disease (PUD) is a common upper gastrointestinal disease. It has been found to be caused by Helicobacter pylori (H. pylori) infection, the overuse of nonsteroidal anti-inflammatory drugs or aspirin, smoking and alcohol consumption [1,2]. If not well treated, PUD may cause gastrointestinal bleeding, obstruction and perforation, which increases the mortality risk and socioeconomic burden [3].

Osteoporosis is a chronic skeletal disease characterized by reduced bone mass. It is a prevalent public health problem in the elderly population, with high fracture risk leading to high morbidity and mortality [4]. Metabolic syndrome (MetS) is a complex multifactorial disorder comprising central obesity, hyperglycemia, hypertriglyceridemia, high blood pressure, and a low concentration of high-density lipoprotein cholesterol (HDL-C). Besides the association with diabetes mellitus and cardiovascular disease, MetS may also be associated with bone metabolism [5,6] and central obesity [7].

H. pylori infection causes a chronic inflammation in the gastric and duodenal mucosa, leading to PUD. This inflammation may not be confined to the digestive tract but also may result in extra-digestive conditions such as osteoporosis [8]. However, the relationship is controversial. An association between H. pylori infection and osteoporosis was reported in a systematic review and meta-analysis by Wang et al. [9], but Kakehasi et al. [10] did not find such an association. However, H. pylori infection is associated with MetS [11–13]. Although PUD, MetS, and osteoporosis are prevalent in the general population, the relationship between PUD, MetS components, and osteoporosis have not been fully studied. This study aimed to investigate the associations between PUD, MetS and its components, and low bone mineral density in a middle-aged healthy population.
2. Materials and Methods

2.1. Study Design and Subjects

This retrospective cross-sectional study was performed using data extracted from the database of the Health Management and Evaluation Center of a tertiary medical center located in southern Taiwan from populations undergoing health examinations between January 2015 and December 2016. The center offers a variety of medical tests and procedures as part of routine physical examinations. Most of the health examinees were undergoing a self-paid physical check-up; others were employees coming for their regular medical check-up. Among 10219 subjects who underwent routine medical check-up at the health examination center, most were free of symptoms. Inclusion criteria were: (1) assessed for metabolic factors; (2) underwent upper gastrointestinal endoscopy and dual energy X-ray absorptiometry scan (DEXA). Exclusion criteria were: (1) did not undergo upper gastrointestinal endoscopy or DEXA; (2) incomplete data; (3) previous or current gastric cancer. Finally, a total of 5102 subjects were included for data analysis. The study protocol was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB No.: 202200895B0) before the study. Signed informed consent of subjects was waived because of the anonymous retrospective nature of the study.

2.2. Measurement of Anthropometric Parameters and Bone Mineral Density

Body weight and height were measured using the same testing equipment (HW-3030, Super-View Medical, Hualien, Taiwan) at the same time with accuracy of 0.1 kg and 1 mm, respectively, as subjects stood erect and were barefoot and wearing light clothing. Body mass index (BMI) was then calculated as weight in kilograms divided by height in meters squared (kg/m\(^2\)). Waist circumference (WC) was measured in centimeters at the mid-level between the iliac crest and the lower border of the 12th rib while subjects stood with feet 25–30 cm apart. BMD values were measured in g/cm\(^2\) by DEXA (Lunar Prodigy Advance; GE Healthcare, Madison, WI, USA) at the lumbar spine, total femoral (total hip), and femoral neck.

2.3. Definition of Metabolic Syndrome and Low Bone Mineral Density

In this study, MetS was defined according to the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) for Asian populations [14]. The modified NCEP ATP III criteria suggested that the cut-off points for WC of Asian populations should use the cut-off of 90 cm in men and 80 cm in women. MetS was diagnosed when at least three of the following five components were found: (1) WC $\geq$ 90 cm for men and $\geq$ 80 cm for women; (2) high blood pressure (systolic blood pressure $\geq$ 130 mm Hg and/or diastolic pressure $\geq$ 85 mm Hg, under treatment, or already diagnosed with hypertension); (3) high serum triglyceride ($\geq$ 150 mg/dL); (4) decreased HDL-C (<40 mg/dL for males and <50 mg/dL for females); and (5) high fasting glucose (FG) $\geq$ 100 mg/dL, under treatment, or previously diagnosed with diabetes mellitus.

The diagnosis of osteoporosis was defined according to the World Health Organization (WHO) definition. The T-score was calculated automatically; the lowest value was chosen for the diagnosis of osteoporosis. Osteoporosis was defined as T-score $\leq$ −2.5; osteopenia as −2.5 < T-score < −1, normal as $\geq$ −1. A definition of low BMD included both osteopenia and osteoporosis.

2.4. Statistical Analyses

Continuous data are presented as mean ± standard deviation (SD) and analyzed by Student’s t test. Categorical data are presented as n (%) and analyzed by the chi-square test. Univariate and multivariate logistic regression was applied to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI) to evaluate associations between outcomes and covariates. Covariates with $p$-value < 0.05 were identified as potential risk factors for outcomes based on the stepwise selection method using logistic regression. The covariates and MetS were entered into model 1, and components of MetS were instead entered as
MetS into model 2. Selected covariates were placed into multivariate logistic regression to assess the associations between variables and outcomes, including PUD, gastric ulcer, and duodenal ulcer. All p values were two-sided and p-value < 0.05 was established as statistical significance. All statistical analyses were performed using the statistical software package SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Prevalence of Peptic Ulcer Disease and Metabolic Syndrome

A total of 5102 subjects were included, with 2159 (42.3%) females and 2943 (57.7%) males. The mean age was 52.4 ± 12.0 years. The prevalence of asymptomatic PUD was 26.1%, including 880 subjects with gastric ulcer and 601 subjects with duodenal ulcer. Additionally, 31.8% subjects were diagnosed with MetS.

3.2. Differences between Subjects with Peptic Ulcer Disease and Non-Peptic Ulcer Disease

Table 1 shows the baseline characteristics between subjects with and without PUD. Subjects with PUD were significantly older (55.9 ± 10.9 vs. 51.2 ± 12.1 years, p < 0.001), with significantly higher BMI (24.7 ± 3.7 vs. 23.9 ± 3.8 kg/m², p < 0.001), WC (84.5 ± 10.7 vs. 81.3 ± 10.8 cm, p < 0.001), systolic blood pressure (SBP) (128.2 ± 19.2 vs. 123.8 ± 18.7 mmHg, p < 0.001), diastolic blood pressure (DBP) (84.8 ± 10.9 vs. 82.6 ± 11.0 mmHg, p < 0.001), fasting glucose (107.1 ± 30.2 vs. 101.4 ± 24.0 mg/dL, p < 0.001), triglycerides (129.2 ± 38.6 vs. 120.8 ± 39.5 mg/dL, p < 0.001), low-density lipoprotein cholesterol (LDL-C) (128.8 ± 34.1 vs. 126.3 ± 35.3 mg/dL, p = 0.025), uric acid (6.6 ± 1.6 vs. 6.3 ± 1.6 mg/dL, p < 0.001), GOT (28.3 ± 20.3 vs. 25.7 ± 14.4 U/L, p < 0.001) and GPT (32.9 ± 32.7 vs. 29.1 ± 22.6 U/L, p < 0.001) compared to those in subjects without PUD. The levels of HDL-C (49.7 ± 13.2 vs. 52.0 ± 13.8 mg/dL, p < 0.001) and eGFR (85.9 ± 20.4 vs. 90.9 ± 20.0 mL/min/1.73 m², p < 0.001) in subjects with PUD were significantly lower than those in subjects without PUD.

Table 1. Differences in baseline characteristics between peptic ulcer disease and non-peptic ulcer disease groups.

| Demography & laboratory data | All (n = 5102) | Peptic Ulcer Disease (n = 1332) | Non-Peptic Ulcer Disease (n = 3770) | p Value |
|-----------------------------|--------------|---------------------------------|-----------------------------------|---------|
| Age, years                  | 52.4 ± 12.0  | 55.9 ± 10.9                      | 51.2 ± 12.1                       | <0.001 *|
| Sex                         |              |                                 |                                   |         |
| Female, n (%)               | 2159 (42.3)  | 413 (31.0)                      | 1746 (46.3)                      | <0.001 *|
| Male, n (%)                 | 2943 (57.7)  | 919 (69.0)                      | 2024 (53.7)                      |         |
| BMI, kg/m²                  | 24.2 ± 3.8   | 24.7 ± 3.7                      | 23.9 ± 3.8                       | <0.001 *|
| WC, cm                      | 82.1 ± 10.9  | 84.5 ± 10.7                     | 81.3 ± 10.8                      | <0.001 *|
| BP, mmHg                    |              |                                 |                                   |         |
| Systolic                    | 124.9 ± 18.9 | 128.2 ± 19.2                    | 123.8 ± 18.7                     | <0.001 *|
| Diastolic                   | 83.2 ± 11.0  | 84.8 ± 10.9                     | 82.6 ± 11.0                      | <0.001 *|
| Fasting glucose, mg/dL      | 102.9 ± 25.9 | 107.1 ± 30.2                    | 101.4 ± 24.0                     | <0.001 *|
| Total cholesterol, mg/dL    | 205.2 ± 39.3 | 206.8 ± 38.6                    | 204.7 ± 39.5                     | 0.09    |
| LDL-C, mg/dL                | 51.4 ± 13.7  | 49.7 ± 13.2                     | 52.0 ± 13.8                      | <0.001 *|
| Triglycerides, mg/dL        | 123.0 ± 87.0 | 129.2 ± 88.4                    | 120.8 ± 86.5                     | 0.002 * |
| HDL-C, mg/dL                | 127.0 ± 35.0 | 128.8 ± 34.1                    | 126.3 ± 35.3                     | 0.025 * |
| Uric acid, mg/dL            | 6.4 ± 1.6    | 6.6 ± 1.6                      | 6.3 ± 1.6                        | <0.001 *|
| eGFR, mL/min/1.73 m² (missing value = 2) | 89.6 ± 20.2 | 85.9 ± 20.4 | 90.9 ± 20.0 | <0.001 * |
| GOT, U/L (missing value = 3) | 26.4 ± 16.2 | 28.3 ± 20.3 | 25.7 ± 14.4 | <0.001 * |
| GPT, U/L (missing value = 2) | 30.1 ± 25.7 | 32.9 ± 32.7 | 29.1 ± 22.6 | <0.001 * |
| Comorbidities               |              |                                 |                                   |         |
| Diabetes, n (%)             | 591 (11.6)   | 208 (15.6)                      | 383 (10.2)                       | <0.001 *|
| Hypertension, n (%)         | 1115 (21.9)  | 359 (27.0)                      | 756 (20.1)                       | <0.001 *|
Table 1. Cont.

|                          | All (n = 5102) | Peptic Ulcer Disease (n = 1332) | Non-Peptic Ulcer Disease (n = 3770) | p Value |
|--------------------------|---------------|---------------------------------|------------------------------------|---------|
| Hyperlipidemia, n (%)    | 214 (4.2)     | 74 (5.6)                        | 140 (3.7)                          | 0.004 * |
| Reflux esophagitis, n (%)| 1452 (28.5)   | 374 (28.1)                      | 1078 (28.6)                        | 0.72    |
| BMD, n (%)               |               |                                 |                                    |         |
| Normal                   | 2553 (50.0)   | 589 (44.2)                      | 1964 (52.1)                        | <0.001 *|
| Osteopenia               | 1903 (37.3)   | 539 (40.5)                      | 1364 (36.2)                        |         |
| Osteoporosis             | 646 (12.7)    | 204 (15.3)                      | 442 (11.7)                         |         |
| MetS, n (%)              | 1620 (31.8)   | 502 (37.7)                      | 1118 (29.7)                        | <0.001 *|

* p < 0.05. BMI: Body mass index, BMD: Bone mineral density, BP: Blood pressure, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, MetS: Metabolic syndrome.

3.3. Univariate and Multivariate Logistic Regression Analyses of Variables Associated with Peptic Ulcer Disease

Results from univariate and multivariate logistic regression analyses are shown in Table 2. Most covariates were associated with higher risk for PUD, except reflux esophagitis and low HDL-C. Model 1 (covariates + MetS) showed that age, sex, BMI, GOT, diabetes, and reflux esophagitis were significantly associated with PUD. Older patients (aOR = 1.03; 95%: 1.03–1.04), male (aOR = 1.80; 95%: 1.56–2.07) or patients with higher BMI (aOR = 1.03; 95%: 1.01–1.05), higher GOT (aOR = 1.00; 95%: 1.00–1.01), diabetes (aOR = 1.23; 95%: 1.02–1.49) had higher risk for PUD. However, reflux esophagitis demonstrated a protective effect for PUD (aOR = 0.81; 95%: 0.70–0.94). Model 2 had similar results, but large WC was a risk factor (aOR = 1.26; 95%: 1.10–1.44), while BMI was not.

Model 1: covariates + MetS using stepwise selection to select risk factors. Model 2: covariates + MetS parameters using stepwise selection to select risk factors. *: Indicates a significant difference, p < 0.05. BMI: Body mass index, BMD: Bone mineral density, BP: Blood pressure, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, MetS: Metabolic syndrome, WC: Waist circumference.
Table 3 shows that most covariates had significant effects on gastric ulcer apart from hyperlipidemia, reflux esophagitis, and low HDL-C. According to the results from model 1 (covariates + MetS), the covariates increased the risk of gastric ulcer, including age (aOR = 1.03; 95%: 1.02–1.04), male (aOR = 1.46; 95%: 1.24–1.71), BMI (aOR = 1.06; 95%: 1.04–1.08), GOT (aOR = 1.004; 95%: 1.00–1.01), and diabetes (aOR = 1.32; 95%: 1.07–1.63). However, reflux esophagitis decreased the risk of developing gastric ulcer (aOR = 0.82; 95%: 0.69–0.97). High triglycerides (aOR = 1.20; 95%: 1.01–1.43) were selected as a new risk factor in model 2, and the results of remaining variables were as in model 1.

Table 3. Risk factors for gastric ulcer disease.

| Variables                          | Univariate |          |          | Multivariate |          |          |
|------------------------------------|------------|----------|----------|--------------|----------|----------|
|                                    | OR (95% CI)| p Value  | aOR (95% CI)| p Value      | aOR (95% CI)| p Value  |
| **Demography & laboratory data**   |            |          |          | Model 1      |          |          |
| Age                                | 1.03 (1.03–1.04) | <0.001 * | 1.03 (1.02–1.04) | <0.001 * | 1.03 (1.02–1.04) | <0.001 * |
| Sex (Male vs. Female)              | 1.66 (1.420–1.93) | <0.001 * | 1.46 (1.24–1.71) | <0.001 * | 1.43 (1.22–1.68) | <0.001 * |
| BMI                                | 1.08 (1.06–1.10) | <0.001 * | 1.06 (1.04–1.08) | <0.001 * | 1.05 (1.03–1.08) | <0.001 * |
| Uric acid                          | 1.00 (1.00–1.00) | 0.027 *  | 1.00 (1.00–1.01) | 0.034 * | 1.00 (1.00–1.01) | 0.045 * |
| eGFR                               | 0.99 (0.98–0.99) | <0.001 * |             |             |             |          |
| GOT                                | 1.01 (1.01–1.11) | <0.001 * |             |             |             |          |
| GPT                                | 1.01 (1.00–1.01) | <0.001 * |             |             |             |          |
| **Comorbidities (vs. No/Normal)**  |            |          |          | Model 1      |          |          |
| Diabetes                           | 1.74 (1.43–2.13) | <0.001 * | 1.32 (1.07–1.63) | 0.010 * | 1.31 (1.06–1.62) | 0.012 * |
| Hypertension                       | 1.57 (1.34–1.85) | <0.001 * |             |             |             |          |
| Hyperlipidemia                     | 1.37 (0.98–1.91) | 0.063    |             |             |             |          |
| Reflux esophagitis, n (%)          | 0.97 (0.83–1.14) | 0.716    | 0.82 (0.69–0.97) | 0.018 * | 0.81 (0.69–0.96) | 0.014 * |
| BMD (vs. Normal)                   |            |          |          | Model 2      |          |          |
| Osteopenia                         | 1.37 (1.17–1.60) | <0.001 * |             |             |             |          |
| Osteoporosis                       | 1.25 (0.99–1.57) | 0.057    |             |             |             |          |
| **MetS and parameter (vs. No/Normal)** |            |          |          | Model 2      |          |          |
| MetS                               | 1.60 (1.38–1.86) | <0.001 * |             |             |             |          |
| Large WC                           | 1.56 (1.35–1.81) | <0.001 * |             |             |             |          |
| High BP                            | 1.44 (1.25–1.67) | <0.001 * |             |             |             |          |
| High Fasting glucose               | 1.65 (1.43–1.91) | <0.001 * |             |             |             |          |
| High Triglycerides                 | 1.45 (1.24–1.70) | <0.001 * |             |             |             |          |
| Low HDL-C                          | 1.14 (0.97–1.33) | 0.103    |             |             |             |          |

Model 1: covariates + MetS using stepwise selection to select risk factors. Model 2: covariates + MetS parameters using stepwise selection to select risk factors. *: Indicates a significant difference, p < 0.05. BMI: Body mass index. BMD: Bone mineral density, BP: Blood pressure, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, MetS: Metabolic syndrome, WC: Waist circumference.

Table 4 lists the covariates significantly associated with duodenal ulcer, including age, sex, eGFR, GOT, GPT, diabetes, osteoporosis, high BP, high fasting glucose in univariate logistic regression. In multivariate logistic regression analysis, age (aOR = 1.03; 95%: 1.02–1.04), male (aOR = 2.20; 95%: 1.81–2.67), and BMD (osteopenia vs. normal; aOR = 1.42; 95%: 1.07–1.88) significantly increased the risk of duodenal ulcer in model 1. Furthermore, compared with model 1, more selected factors were found in model 2, including low HDL-C (aOR = 1.31; 95%: 1.07–1.59) and high triglycerides (aOR = 0.67; 95%: 0.55–0.85).
Table 4. Risk factors for duodenal ulcer disease.

| Variables                      | Univariate OR (95% CI) | p Value | Multivariate Model 1 aOR (95% CI) | p Value | Multivariate Model 2 aOR (95% CI) | p Value |
|--------------------------------|------------------------|---------|----------------------------------|---------|----------------------------------|---------|
| **Demography & laboratory data** |                        |         |                                  |         |                                  |         |
| Age                            | 1.03 (1.03–1.04)        | <0.001  | 1.03 (1.02–1.04)                 | <0.001  | 1.03 (1.02–1.04)                 | <0.001  |
| Sex (Male vs. Female)          | 2.12 (1.76–2.56)        | <0.001  | 2.20 (1.81–2.67)                 | <0.001  | 2.35 (1.92–2.86)                 | <0.001  |
| BMI                            | 1.02 (0.96–1.04)        | 0.134   |                                  |         |                                  |         |
| Uric acid                      | 1.00 (0.99–1.00)        | 0.539   |                                  |         |                                  |         |
| eGFR                           | 0.99 (0.98–0.99)        | <0.001  |                                  |         |                                  |         |
| GOT                            | 1.01 (1.00–1.01)        | 0.010   |                                  |         |                                  |         |
| GPT                            | 1.00 (1.00–1.01)        | 0.004   |                                  |         |                                  |         |
| **Comorbidities (vs. No/Normal)** |                        |         |                                  |         |                                  |         |
| Diabetes                       | 1.49 (1.18–1.90)        | 0.001   |                                  |         |                                  |         |
| Hypertension                   | 1.21 (0.99–1.47)        | 0.064   |                                  |         |                                  |         |
| Hyperlipidemia                 | 1.34 (0.91–1.96)        | 0.142   |                                  |         |                                  |         |
| Reflux esophagitis, n (%)      | 1.76 (0.86–3.04)        | 0.444   |                                  |         |                                  |         |
| **BMD (vs. Normal)**           |                        |         |                                  |         |                                  |         |
| Osteopenia                     | 1.19 (0.99–1.44)        | 0.065   | 0.88 (0.71–1.09)                 | 0.233   | 0.88 (0.71–1.09)                 | 0.254   |
| Osteoporosis                   | 1.89 (1.49–2.40)        | <0.001  | 1.42 (1.07–1.88)                 | 0.015   | 1.44 (1.08–1.91)                 | 0.012   |
| **MetS and parameter (vs. No/Normal)** |                      |         |                                  |         |                                  |         |
| MetS                           | 1.13 (0.94–1.35)        | 0.186   |                                  |         |                                  |         |
| Large WC                       | 1.18 (0.99–1.41)        | 0.066   |                                  |         |                                  |         |
| High BP                        | 1.27 (1.07–1.51)        | 0.006   |                                  |         |                                  |         |
| High Fasting glucose           | 1.33 (1.12–1.58)        | 0.001   |                                  |         |                                  |         |
| High Triglycerides             | 0.85 (0.70–1.04)        | 0.118   |                                  |         |                                  |         |
| Low HDL-C                      | 1.14 (0.95–1.37)        | 0.167   |                                  |         |                                  |         |

Model 1: covariates + MetS using stepwise selection to select risk factors. Model 2: covariates + MetS parameters using stepwise selection to select risk factors. *: Indicates a significant difference, p < 0.05. BMI: Body mass index, BMD: Bone mineral density, BP: Blood pressure, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, MetS: Metabolic syndrome, WC: Waist circumference.

4. Discussion

The prevalence of asymptomatic PUD and MetS are increasing in Taiwan. The prevalence of asymptomatic PUD was 9.4% in 2008 [15] and age-standardized prevalence of MetS was 15.7% by the modified ATP III criteria in 2002 [16]. In the present study, the prevalence of PUD and MetS was 26.1% and 31.9%, respectively. Results of the present study show that the dominant risk factors for PUD in a healthy middle-aged population are age, sex, GOT, diabetes, and large WC. MetS is not associated with PUD, but gastric ulcer is associated with a high TG level, while duodenal ulcer is associated with a low HDL level and osteoporosis.

The present study shows that BMI and large WC are associated with PUD. Previous studies have proposed that abdominal obesity implicates digestive system diseases because the altered secretion of adipocytokines from accumulated visceral fat is associated with various pathophysiological conditions, including insulin resistance and inflammation. This inflammation may further cause gastrointestinal mucosal injury, leading to PUD [17,18]. Nevertheless, the relationship between PUD and obesity, including total obesity and central obesity, remains controversial [7,15,19–21]. Some studies have reported obesity as a risk factor for PUD [7,15,20,21], but Tsai et al. [19] did not observe a significant association between BMI and PUD. The underlying mechanism that prompts obesity to increase the risk of asymptomatic PUD is unclear. Several possible explanations have been suggested. In obese subjects, increased intra-abdominal pressure may cause more acid secretion [22]. Wisén et al. [23] used the gastric acid secretion test after modified sham feeding to show that obese patients had higher gastric acid secretion than non-obese patients. Adipose tissue is an endocrine organ involved in the development and occurrence of inflammation by secreting adipokines [24,25]. Adipose tissue and inflammatory cells may promote...
inflammation and insulin resistance, resulting in the expression of adhesion molecules and pro-inflammatory cytokines [26]. These factors together induce chronic low-grade inflammation of the body and induce PUD.

The present study has shown that MetS is not associated with PUD, but its components are. Triglycerides are positively associated with gastric ulcer but negatively associated with duodenal ulcer, while low HDL is associated with duodenal ulcer. The relationship between serum lipid levels and PUD varies in different populations. Kim et al. [27] showed that triglycerides are associated with PUD in men but not in women. In addition, H. pylori infection significantly affects serum lipid profiles. Studies have reported that H. pylori infection is positively associated with TG and negatively associated with HDL-C [11,28]. Further study is needed to determine why triglycerides display conflicting associations between gastric and duodenal ulcers.

Results of the present study have shown that duodenal ulcers are associated with osteoporosis, which is probably related to reduced calcium absorption in the inflamed duodenal mucosa. Several studies have also shown an association between PUD and osteoporosis [29–31], but a systematic review and cumulative analysis found that only men had a positive association between PUD and osteoporosis, while women with PUD did not have a higher risk of osteoporosis when compared with the general population [32].

Diabetes mellitus is associated with PUD, especially gastric ulcer. Previous studies have reported a high prevalence of PUD in patients with diabetes mellitus [33–35]. A possible explanation is the significantly higher prevalence of H. pylori infection in patients with type II diabetes [36]. In addition, diabetic angiopathy and the use of antiplatelet medications in diabetic patients may impair the integrity of the gastric mucosa, causing ulcer formation [37].

Besides the factors stated above, gut microbiota also plays important roles in many diseases including obesity and metabolic syndromes [38]. It was reported that intestinal microbiota controlled Th17 cells which regulated innate immune response and lipid absorption across intestinal epithelium [39,40]. Intestinal microbiota can also degrade indigestible polysaccharides and secrete short chain fatty acids (SCFA) which can be transported elsewhere and affect cellular function [41]. Insufficient amount of SCFA weakens the tight junction and makes the intestinal epithelial barrier leaky [42,43]. This facilitates the infection of H. pylori and the progressing of inflammation bowel diseases [38,44].

The present study analyzed the risk factors for PUD in middle-aged population. Keeping regular hours, ration size, and meal schedule are important for high-risk populations. To avoid PUD, good control of BMI, waist circumference, GOT, and triglycerides level is recommended for male subjects, especially for those with old age or diabetes. For male subjects with osteoporosis, good control of HDL level is recommended to avoid duodenal ulcer.

The present study has several limitations. First, the data were extracted from an administrative computer database that did not include medication and lifestyle factors such as aspirin use, smoking, and alcoholic consumption that may induce PUD formation and therefore, these factors could not be adjusted in the statistical models. Second, the retrospective cross-sectional study design did not allow causal relationships to be inferred. Third, the study subjects were from a single health-promotion center in southern Taiwan and study results may not be representative of the general population or other ethnic populations. Fourth, the data from 2015–2016 were used because of the largest population size for analysis. Hence, they may not completely reflect the current associations.

5. Conclusions

Central obesity is associated with PUD in a general middle-aged population. High triglycerides are associated with gastric ulcer, while low HDL-C and osteoporosis are associated with duodenal ulcer. Further prospective cohort studies are warranted to clarify the cause-and-effect relationships.

Author Contributions: Conceptualization, S.-S.L. and W.-C.L.; methodology, S.-S.L. and W.-C.L.; software, S.-S.L.; validation, S.-S.L. and W.-C.L.; formal analysis, S.-S.L.; data curation, S.-S.L.;
writing—original draft preparation, S.-S.L. and W.-C.L.; writing—review and editing, S.-S.L.; project administration, S.-S.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study protocol was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB No.: 202200895B0).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The datasets generated and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Acknowledgments:** We appreciate the assistance of the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Makola, D.; Peura, D.A.; Crowe, S.E. Helicobacter pylori infection and related gastrointestinal diseases. *J. Clin. Gastroenterol.* 2007, 41, 548–558. [CrossRef] [PubMed]

2. Rosenstock, S.; Jorgensen, T.; Bonnevie, O.; Andersen, L. Risk factors for peptic ulcer disease: A population based prospective cohort study comprising 2416 Danish adults. *Gut* 2003, 52, 186–193. [CrossRef] [PubMed]

3. Lau, J.Y.; Sung, J.; Hill, C.; Henderson, C.; Howden, C.W.; Metz, D.C. Systematic Review of the Epidemiology of Complicated Peptic Ulcer Disease: Incidence, Recurrence, Risk Factors and Mortality. *Digestion* 2011, 84, 102–113. [CrossRef] [PubMed]

4. Johnell, O.; Kamis, J.A. An estimated of worldwide prevalence and disability associated with osteoporosis fractures. *Osteoporos. Int.* 2006, 17, 1726–1733. [CrossRef] [PubMed]

5. Hwang, D.K.; Choi, H.J. The relationship between low bone mass and metabolic syndrome in Korean women. *Osteoporos. Int.* 2010, 21, 425–431. [CrossRef] [PubMed]

6. Park, K.K.; Kim, S.J.; Moon, E.S. Association between bone mineral density and metabolic syndrome in postmenopausal Korean women. *Gynecol. Obstet. Invest.* 2010, 69, 145–152. [CrossRef] [PubMed]

7. Boylan, M.R.; Khalili, H.; Huang, E.S.; Chan, A.T. Measures of adiposity are associated with increased risk of peptic ulcer. *Clin. Gastroenterol. Hepatol.* 2014, 12, 1688–1694. [CrossRef]

8. Ding, C.; Parameswaran, V.; Udayan, R.; Burgess, J.; Jones, G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: A longitudinal study. *J. Clin. Endocrinol. Metab.* 2008, 93, 1952–1958. [CrossRef] [PubMed]

9. Wang, T.; Li, X.; Zhang, Q.; Ge, B.; Zhang, J.; Yu, L.; Cai, T.; Zhang, Y.; Xiong, H. Relationship between Helicobacter pylori infection and related gastrointestinal diseases. *J. Clin. Gastroenterol.* 2007, 41, 548–558. [CrossRef] [PubMed]

10. Kakehasi, C.; Mendes, M.C.; Coelho, L.G.V.; Castro, L.P.; Barbosa, A.J.A. The presence of Helicobacter pylori infection in postmenopausal women is not a factor to the decrease of bone mineral density. *Arg. Gastroenterol.* 2007, 44, 266–270. [CrossRef] [PubMed]

11. Lim, S.H.; Kim, N.; Kwon, J.W.; Kim, S.E.; Baik, G.H.; Lee, J.Y.; Park, K.S.; Shin, J.E.; Song, H.J.; Myung, D.S.; et al. Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: A multicenter nationwide study. *Dig. Dis. Sci.* 2019, 64, 2219–2230. [CrossRef]

12. Refaeli, R.; Chodick, G.; Haj, S.; Goren, S.; Shalev, V.; Mulsen, K. Relationship of H. pylori infection and its related gastroduodenal morbidity with metabolic syndrome: A large cross-sectional study. *Sci. Rep.* 2018, 8, 4088. [CrossRef]

13. Chen, T.P.; Hung, H.F.; Chen, M.K.; Lai, H.H.; Hsu, W.F.; Huang, K.C.; Yang, K.C. Helicobacter pylori infection is positively associated with metabolic syndrome in Taiwanese adults: A cross-sectional study. *Helicobacter* 2015, 20, 184–191. [CrossRef] [PubMed]

14. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005, 112, 2735–2752. [CrossRef]

15. Wang, F.W.; Tu, M.S.; Mar, G.Y.; Chuang, H.Y.; Yu, H.C.; Cheng, L.C.; Hsu, P.I. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. *World J. Gastroenterol.* 2011, 17, 1199–1203. [CrossRef] [PubMed]

16. Hwang, L.C.; Bai, C.H.; Chen, C.J. Prevalence of obesity and metabolic syndrome in Taiwan. *J. Formos. Med. Assoc.* 2006, 105, 626–635. [CrossRef] [PubMed]

17. Sugabe, M.; Okahisa, T.; Kimura, T.; Okamoto, K.; Miyamoto, H.; Muguruma, N.; Takayama, T. Influence of metabolic syndrome on upper gastrointestinal disease. *Clin. J. Gastroenterol.* 2016, 9, 191–202. [CrossRef] [PubMed]

18. Ding, S.; Chi, M.M.; Scull, B.P.; Rigby, R.; Schwerbrock, N.M.J.; Magness, S.; Jobin, C.; Lund, P.K. High-fat diet: Bacteria interactions promote intestinal inflammation which preceeds and correlates with obesity and insulin resistance in mouse. *PLoS ONE* 2010, 5, e12191. [CrossRef] [PubMed]

19. Tsai, W.L.; Yang, C.Y.; Lin, S.F.; Fang, F.M. Impact of obesity on medical problems and quality of life in Taiwan. *Am. J. Epidemiol.* 2004, 160, 557–565. [CrossRef]
20. Lee, B.J.; Kim, J.; Kim, K.H. Association of gastric and duodenal ulcers with anthropometry and nutrients: Korean national health and nutrition examination survey (knhanes ii–iv) 2001–2009. PLoS ONE 2017, 12, e0183777. [CrossRef] [PubMed]
21. Garrow, D.; Delegge, M.H. Risk factors for gastrointestinal ulcer disease in the US population. Dig. Dis. Sci. 2010, 55, 66–72. [CrossRef] [PubMed]
22. Barak, N.; Ehrenpreis, E.D.; Harrison, J.R.; Sitrin, M.D. Gastro-oesophageal reflux disease in obesity: Pathophysiological and therapeutic considerations. Obes. Rev. 2002, 3, 9–15. [CrossRef] [PubMed]
23. Wisén, O.; Rössner, S.; Johansson, C. Gastric secretion in massive obesity. Evidence for abnormal response to vagal stimulation. Dig. Dis. Sci. 1987, 32, 968–972. [CrossRef] [PubMed]
24. Gonçalves, P.; Magro, F.; Martel, F. Metabolic inflammation in inflammatory bowel disease: Crosstalk between adipose tissue and bowel. Inflamm. Bowel Dis. 2015, 21, 453–467. [CrossRef]
25. Kahn, C.R.; Wang, G.; Lee, K.Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J. Clin. Investig. 2019, 129, 3990–4000. [CrossRef] [PubMed]
26. Karmiris, K.; Koutroubakis, I.E.; Xidakis, C.; Polychronaki, M.; Kouroumalis, E.A. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2007, 19, 789–794. [CrossRef] [PubMed]
27. Kim, J.; Kim, K.H.; Lee, B.J. Association of peptic ulcer disease with obesity, nutritional components, and blood parameters in the Korean population. PLoS ONE 2017, 12, e0183777. [CrossRef] [PubMed]
28. Shimamoto, T.; Yamamichi, N.; Gondo, K.; Takahashi, Y.; Takeuchi, C.; Wada, R.; Mitsushima, T.; Koike, K. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE 2020, 15, e0234433. [CrossRef]
29. Choi, H.G.; Rhim, C.C.; Yoon, J.Y.; Park, B.J.; Min, C.Y.; Lee, S.W. Increased risk of osteoporosis in patients with peptic ulcer: A follow-up study using a national sample cohort. Arch. Osteoporos. 2019, 14, 105. [CrossRef] [PubMed]
30. Yoon, P.H.; An, S.J.; Jeong, S.H.; Yang, Y.J.; Hong, Y.P. Association between peptic ulcer disease and osteoporosis: The population-based longitudinal cohort study in Korea. Int. J. Environ. Res. Public Health 2019, 16, 2777. [CrossRef] [PubMed]
31. Lai, S.W.; Kuo, Y.H.; Liao, K.F. Association between peptic ulcer disease and osteoporosis. Arch. Osteoporos. 2020, 15, 39. [CrossRef] [PubMed]
32. Zhao, S.; Ding, L.; Xie, Q.; Zhang, J.; Yang, S.; Xu, W.; Yang, J.; Xu, Y.; Zheng, C. Is there an association between peptic ulcer disease and osteoporosis: A systematic review and cumulative analysis. Eur. J. Gastroenterol. Hepatol. 2021, 33, 9–16. [CrossRef] [PubMed]
33. Boehme, M.W.; Autschbach, F.; Ell, C.; Raeth, U. Prevalence of silent gastric ulcer, erosions or severe acute gastritis in patients with type 2 diabetes mellitus—A cross-sectional study. Hepatogastroenterology 2007, 54, 643–648. [PubMed]
34. Parkman, H.P.; Schwartz, S.S. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch. Intern. Med. 1987, 147, 1477–1480. [CrossRef]
35. Tseng, P.H.; Lee, Y.C.; Chiu, H.M.; Chen, C.C.; Liao, W.C.; Tu, C.H.; Yang, W.S.; Wu, M.S. Association of diabetes and HbA1c levels with gastrointestinal manifestations. Diabetes Care 2012, 35, 1053–1060. [CrossRef] [PubMed]
36. Yang, G.H.; Wu, J.S.; Yang, Y.C.; Huang, Y.H.; Lu, F.H.; Chang, C.J. Gastric helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J. Gastroenterol. Hepatol. 2014, 29, 1794–1799. [CrossRef] [PubMed]
37. Weil, J.; Langman, M.J.; Wainwright, P.; Lawson, D.H.; Rawlins, M.; Logan, R.E.; Brown, T.P.; Vessey, M.P.; Murphy, M.; Colin-Jones, D.G. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000, 46, 27–31. [CrossRef] [PubMed]
38. Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J. 2017, 474, 1823–1836. [CrossRef]
39. Kawano, Y.; Edwards, M.; Huang, Y.; Bilate, A.M.; Araujo, L.P.; Tanoue, T.; Atarashi, K.; Ladinsky, M.S.; Reiner, S.L.; Wang, H.H.; et al. Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome. Cell 2022, 188, 3515–3519.e20. [CrossRef] [PubMed]
40. Adolph, T.E.; Meyer, M.; Schwärzler, J.; Mayr, L.; Grabbett, F.; Tilg, H. The metabolic nature of inflammatory bowel diseases. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 753–767. [CrossRef] [PubMed]
41. Silva, Y.P.; Bernardi, A.; Frozza, R.L. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front. Endocrinol. 2020, 11, 25. [CrossRef] [PubMed]
42. Pérez-Reytor, D.; Puebla, C.; Karahanian, E.; García, K. Use of Short-Chain Fatty Acids for the Recovery of the Intestinal Epithelial Barrier Affected by Bacterial Toxins. Front. Physiol. 2021, 12, 650313. [CrossRef] [PubMed]
43. Singh, R.; Zogg, H.; Wei, L.; Bartlett, A.; Ghoshal, U.C.; Rajender, S.; Ro, S. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. J. Neurogastroenterol. Motil. 2021, 27, 19–34. [CrossRef] [PubMed]
44. Martin-Núñez, G.M.; Cornejo-Pareja, I.; Clemente-Postigo, M.; Tinhonnes, F.J. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front. Endocrinol. 2021, 12, 639856. [CrossRef]